Enhanced laboratory surveillance for the elimination of rubella and congenital rubella syndrome in the Americas.

One of the reasons the 1997 Technical Advisory Group on Vaccine-Preventable Diseases recommended acceleration of rubella and congenital rubella syndrome (CRS) prevention efforts was the fact that the enhanced measles surveillance system in the Americas found that 25% of reported measles cases were laboratory-confirmed rubella cases. Until 1997, the laboratory network primarily focused on measles diagnosis. Since 1999, due to the accelerated rubella control and CRS prevention strategy, laboratories have supported the regional measles, rubella, and CRS elimination goals. The measles-rubella laboratory network established in the Americas provides timely confirmation or rejection of suspected measles and rubella cases, and determination of the genotypic characteristics of circulating virus strains, critical information for the programs. A quality assurance process has ensured high-quality performance of procedures in the network. Challenges are occurring, but the measles-rubella laboratory network continues to adapt as the requirements of the program change, demonstrating the high quality of the laboratories in support of public health activities and elimination goals.

[1]  E. Abernathy,et al.  Genetic analysis of rubella viruses found in the United States between 1966 and 2004: evidence that indigenous rubella viruses have been eliminated. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Wynne,et al.  Simultaneous IgM reactivity by EIA against more than one virus in measles, parvovirus B19 and rubella infection. , 1999, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  B. Thomas,et al.  Application of molecular and serological assays to case based investigations of rubella and congenital rubella syndrome , 2007, Journal of medical virology.

[4]  V. Dietz,et al.  The Measles Laboratory Network in the region of the Americas. , 2003, The Journal of infectious diseases.

[5]  E. Abernathy,et al.  Dried Blood Spots versus Sera for Detection of Rubella Virus-Specific Immunoglobulin M (IgM) and IgG in Samples Collected during a Rubella Outbreak in Peru , 2007, Clinical and Vaccine Immunology.

[6]  J. Furesz Elimination of measles in the Americas. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  M. C. Danovaro-Holliday,et al.  Feasibility of global measles eradication after interruption of transmission in the Americas , 2008, Expert Review of Vaccines.

[8]  G. E. King,et al.  Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. , 1996, The Journal of infectious diseases.

[9]  Tong-zhan Wang,et al.  Comparison of Four Methods Using Throat Swabs To Confirm Rubella Virus Infection , 2007, Journal of Clinical Microbiology.

[10]  Progress toward measles elimination--region of the Americas, 2002-2003. , 2004, MMWR. Morbidity and mortality weekly report.

[11]  W. Bellini,et al.  The laboratory confirmation of suspected measles cases in settings of low measles transmission: conclusions from the experience in the Americas. , 2004, Bulletin of the World Health Organization.

[12]  Progress toward elimination of rubella and congenital rubella syndrome--the Americas, 2003-2008. , 2008, MMWR. Morbidity and mortality weekly report.

[13]  E. Miller,et al.  CONSEQUENCES OF CONFIRMED MATERNAL RUBELLA AT SUCCESSIVE STAGES OF PREGNANCY , 1982, The Lancet.

[14]  J. Andrus,et al.  Recent advances in immunization , 2006 .

[15]  W. Bellini,et al.  Interpretation of measles and rubella serology. , 2006 .

[16]  M. Takeda,et al.  Measles virus: cellular receptors, tropism and pathogenesis. , 2006, The Journal of general virology.

[17]  G. Miranda-Novales,et al.  Prevalence of serological markers against measles, rubella, varicella, hepatitis B, hepatitis C, and human immunodeficiency virus among medical residents in Mexico. , 2001, Preventive medicine.

[18]  H. Kelly,et al.  Interruption of rubella virus transmission in Australia may require vaccination of adult males: evidence from a Victorian sero-survey. , 2004, Communicable diseases intelligence quarterly report.

[19]  M. Beller,et al.  False positive rubeola IgM tests. , 1995, The New England journal of medicine.

[20]  D. Samuel,et al.  Evaluation of a commercial rubella IgM assay for use on oral fluid samples for diagnosis and surveillance of congenital rubella syndrome and postnatal rubella. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  S. Ratnam,et al.  Evaluation of rubella IgM enzyme immunoassays. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  J. Icenogle,et al.  An indirect immunocolorimetric assay to detect rubella virus infected cells. , 2007, Journal of virological methods.

[23]  E. Vynnycky,et al.  Modelling the incidence of congenital rubella syndrome in developing countries. , 1999, International journal of epidemiology.

[24]  S. Robertson,et al.  Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India. , 2004, Bulletin of the World Health Organization.

[25]  E. Abernathy,et al.  Confirmation of Rubella within 4 Days of Rash Onset: Comparison of Rubella Virus RNA Detection in Oral Fluid with Immunoglobulin M Detection in Serum or Oral Fluid , 2008, Journal of Clinical Microbiology.

[26]  Global distribution of measles and rubella genotypes--update. , 2006, Releve epidemiologique hebdomadaire.

[27]  D. Brown,et al.  Development of the Global Measles Laboratory Network. , 2003, The Journal of infectious diseases.

[28]  S. Reef,et al.  New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas. , 2003, The Journal of infectious diseases.

[29]  J. Andrus,et al.  Elimination of rubella and congenital rubella syndrome in the Americas: another opportunity to address inequities in health. , 2004, Revista panamericana de salud publica = Pan American journal of public health.

[30]  E. Abernathy,et al.  Identification of strain-specific nucleotide sequences in the RA 27/3 rubella virus vaccine. , 1993, The Journal of infectious diseases.

[31]  D A Henderson,et al.  Measles elimination in the Americas. Evolving strategies. , 1996, JAMA.

[32]  K. Terada Rubella and congenital rubella syndrome in Japan: epidemiological problems. , 2003, Japanese journal of infectious diseases.

[33]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[34]  H. Thomas,et al.  Persistent rubella‐specific IgM reactivity in the absence of recent primary rubella and rubella reinfection , 1992, Journal of medical virology.

[35]  W. Bellini,et al.  Measles and Rubella Viruses , 2011 .

[36]  C. D. de Quadros,et al.  [Accelerated rubella control and the prevention of congenital rubella syndrome]. , 2002, Revista panamericana de salud publica = Pan American journal of public health.